Progressive pulmonary fibrosis in hamsters.

Area of Science:

• Pulmonary Medicine
• Toxicology
• Pathology

Background:

• Bleomycin is a chemotherapy agent known to cause lung toxicity.
• Hyperoxia (high oxygen levels) can also induce lung injury.
• The combined effects of bleomycin and hyperoxia on lung injury are not fully understood.

Purpose of the Study:

• To investigate the synergistic effects of bleomycin and hyperoxia on pulmonary injury in a hamster model.
• To characterize the histopathological and functional changes in the lungs over time.
• To establish a relevant animal model for studying human pulmonary fibrosis.

Main Methods:

• Hamsters received intratracheal bleomycin followed by exposure to 70% oxygen for 72 hours.
• Animals were assessed at multiple time points (3-120 days) using histopathology and morphometry.
• In vivo pulmonary function tests were conducted at 25 and 55 days.

Main Results:

• Concomitant bleomycin and hyperoxia induced acute diffuse alveolar damage.
• Lung disease peaked at 10 days (33.5%), improved by 30 days (10.5%), then progressed to diffuse pneumonitis with fibrosis (30-38%) by 120 days.
• Pulmonary function tests showed decreased dynamic compliance and increased minute ventilation, consistent with fibrosis.

Conclusions:

• Simultaneous bleomycin and hyperoxia treatment in hamsters creates a model of interstitial fibrosis that closely resembles human pulmonary fibrosis.
• This model is suitable for studying the progression of widely distributed fibrotic lung disease.
• The findings highlight the synergistic toxicity of bleomycin and hyperoxia, leading to progressive lung damage.